Tumor targeted siRNA delivery by adenosine receptor-specific curdlan nanoparticles

被引:5
作者
Bao, Qingming [1 ]
Ganbold, Tsogzolmaa [1 ]
Bao, Mingming [1 ]
Xiao, Hai [1 ]
Han, Shuqin [1 ]
Baigude, Huricha [1 ,2 ]
机构
[1] Inner Mongolia Univ, Sch Chem & Chem Engn, Inner Mongolia Key Lab Mongolian Med Chem, Hohhot 010020, Inner Mongolia, Peoples R China
[2] Inner Mongolia Univ, Sch Chem & Chem Engn, Hohhot 010020, Peoples R China
基金
中国国家自然科学基金;
关键词
siRNA delivery; Adenosine receptor; Melanoma; Curdlan nanoparticles; STAT3; IN-VIVO; CANCER; THERAPEUTICS;
D O I
10.1016/j.ijbiomac.2023.126845
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aminated curdlan derivatives are highly effective nucleic acid carriers. Previously, we proved that the ligand-functionalized curdlan derivatives have greatly enhanced cell type specificity induced by receptor-mediated internalization in vitro. In this study, to improve biocompatibility and enhance tumor-targeting efficacy of the curdlan derivative, we pegylated the adenosine functionalized amino curdlan derivative (denoted by pAVC polymer). We confirmed that the uptake of pAVC polymer carrying siRNA by tumor cells was adenosine receptor (AR)-dependent and was specifically inhibited by AMP but not by GMP. The pAVC polymers not only preserved the receptor recognition and exhibited significantly decreased cytotoxicity but also showed remarkable tumor targeting efficiency in vivo. The nanoparticles formulated from siRNA (against STAT3) and pAVC4 polymer, which bears the highest degree of PEG substitution, delivered siRNA highly specifically to tumor tissue, knocked down STAT3, and inhibited tumor growth. The pAVC polymers may be a promising carrier for tumor specific delivery of nucleic acid drugs.
引用
收藏
页数:10
相关论文
共 24 条
  • [11] Targeting STAT3 affects melanoma on multiple fronts
    Kortylewski, M
    Jove, R
    Yu, H
    [J]. CANCER AND METASTASIS REVIEWS, 2005, 24 (02) : 315 - 327
  • [12] Tumor-Targeting Multifunctional Nanoparticles for siRNA Delivery: Recent Advances in Cancer Therapy
    Ku, Sook Hee
    Kim, Kwangmeyung
    Choi, Kuiwon
    Kim, Sun Hwa
    Kwon, Ick Chan
    [J]. ADVANCED HEALTHCARE MATERIALS, 2014, 3 (08) : 1182 - 1193
  • [13] siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes
    Matsuda, Shigeo
    Keiser, Kristofer
    Nair, Jayaprakash K.
    Charisse, Klaus
    Manoharan, Rajar M.
    Kretschmer, Philip
    Peng, Chang G.
    Kel'in, Alexander V.
    Kandasamy, Pachamuthu
    Willoughby, Jennifer L. S.
    Liebow, Abigail
    Querbes, William
    Yucius, Kristina
    Tuyen Nguyen
    Milstein, Stuart
    Maier, Martin A.
    Rajeev, Kallanthottathil G.
    Manoharan, Muthiah
    [J]. ACS CHEMICAL BIOLOGY, 2015, 10 (05) : 1181 - 1187
  • [14] MATSUMURA Y, 1986, CANCER RES, V46, P6387
  • [15] Synthesis of PEGylated cationic curdlan derivatives with enhanced biocompatibility
    Muqier, Muqier
    Xiao, Hai
    Yu, Xiang
    Li, Yifeng
    Bao, Mingming
    Bao, Qingming
    Han, Shuqin
    Baigude, Huricha
    [J]. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2022, 33 (04) : 465 - 480
  • [16] Novel fusion peptide-mediated siRNA delivery using self-assembled nanocomplex
    Ryu, Yeong Chae
    Kim, Kyung Ah
    Kim, Byoung Choul
    Wang, Hui-Min David
    Hwang, Byeong Hee
    [J]. JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19 (01)
  • [17] Protein coronas suppress the hemolytic activity of hydrophilic and hydrophobic nanoparticles
    Saha, Krishnendu
    Moyano, Daniel F.
    Rotello, Vincent M.
    [J]. MATERIALS HORIZONS, 2014, 1 (01) : 102 - 105
  • [18] Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression
    Sorrentino, Claudia
    Miele, Lucio
    Porta, Amalia
    Pinto, Aldo
    Morello, Silvana
    [J]. ONCOTARGET, 2016, 7 (39) : 64274 - 64288
  • [19] Sun Y, 2016, FRONT CHEM, V4, DOI [10.3339/fchem.2016.00037, 10.3389/fchem.2016.00037]
  • [20] Tanaka Y, 2020, BIOL PHARM BULL, V43, P516, DOI 10.1248/bpb.b19-00976